- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Spondyloarthritis
Xenofon Baraliakos, MD: Efficacy and Safety of Bimekizumab in Non-Radiographic Axial Spondyloarthritis
November 14, 2022
ASAS40 responses increased between week 16 and week 52 in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Upadacitinib Receives Positive CHMP Opinion for Treatment of Non-Radiographic Axial Spondyloarthritis
June 28, 2022
The Committee for Medicinal Products for Human Use (CHMP) recommends approving upadacitinib 15 mg, once daily, for the treatment of active non-radiographic axial spondyloarthritis in adults patients with inflammation and inadequate response to NSAIDs.
Désirée van der Heijde, MD, PhD: Safety, Efficacy of Bimekizumab in Ankylosing Spondyloarthritis
June 14, 2022
Désirée van der Heijde, MD, PhD, explains the results of a recent trial evaluating the safety and efficacy of bimekizumab in patients with active ankylosing spondylitis.
Filip Van den Bosch, MD: Safety and Efficacy of Upadacitinib for nr-axSpA
June 03, 2022
Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."
Upadacitinib Achieves Promising Results for Axial Spondyloarthritis Treatment
June 03, 2022
Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.
Poor Exercise Adherence Reported in Patients with Ankylosing Spondylitis
May 11, 2022
Of 185 outpatients that completed the questionnaire, 146 patients (78.9%) were considered to have poor adherence to exercise therapy.
Increased Risk of Aortic Regurgitation, Atrial Fibrillation in Patients With Radiographic Axial Spondyloarthritis
May 04, 2022
The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.
Secukinumab Improves Disease Activity in Patients With PsA, axSpA
April 25, 2022
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.
Pregnancy Complications More Prevalent in Women With Axial Spondyloarthritis
March 22, 2022
“Understanding the impact of axSpA on pregnancy outcomes is a vital component of improving management of women with axSpA at every stage of their lives,” investigators stated.
Bimekizumab Meets Primary and Secondary Endpoints for Treating Axial Spondyloarthritis
January 18, 2022
Bimekizumab, an interleukin 17A (IL-17A) and IL-17F inhibitor, met both primary and secondary endpoints for treating adult patients with non-radiographic axial spondyloarthritis.